AI Is Flooding Drug Discovery With Candidates. Clinical Validation Has No Flood Gates.
AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most...
Research Billing Is a False Claims Act Surface. Treat the MCA Like the Control It Is.
A stale or vague Medical Coverage Analysis is worse than none when an auditor arrives. Here is why the...
The Dystrophin Standard: How a 1% Biomarker Signal Became a $967 Million Accelerated Approval Precedent
FDA granted four DMD antisense oligonucleotide accelerated approvals on ~1 percentage-point dystrophin increases. With $967M in annual revenue on...
Icotrokinra’s NEJM Data Reveals the Quiet Shift in How UC Trials Get Designed and Approved
J&J's icotrokinra hit every UC endpoint in NEJM's Oct 2026 data, and the trial design choices behind that success...
FDA Clears Combined Use of Restrata Matrix With Solventum V.A.C. Therapy
FDA clears combined use of Restrata Matrix with Solventum V.A.C. Therapy for integrated wound care, enabling simultaneous application of...
FDA Clears Haemonetics PerQseal Elite Vascular Closure System
FDA clears Haemonetics PerQseal Elite vascular closure system for large-bore arterial procedures, showing zero major complications in clinical trial.
UP Oncolytics Gets $2.5M NIH Funding for Zika Virus Glioblastoma Therapy
UP Oncolytics secures $2.5M NIH funding to advance engineered Zika virus glioblastoma therapy toward first human trial, leveraging the...
SpyGlass Pharma’s Bimatoprost Pad-IOL Shows Four-Year Durability Data
SpyGlass Pharma's Bimatoprost Pad-IOL demonstrates four-year durability in first-in-human trial, supporting two ongoing Phase 3 studies for sustained glaucoma...
ArriVent’s Firmonertinib Phase 1b Data Published in Cancer Cell
ArriVent's firmonertinib Phase 1b data published in Cancer Cell, targeting EGFR PACC mutations resistant to standard inhibitors in NSCLC.
Orforglipron’s MACE Data Just Raised the Evidentiary Bar for Every Oral GLP-1 Program Behind It
Orforglipron's ACHIEVE-4 trial showed MACE-4 in 4.2% vs. 5.0% for insulin glargine, now every oral small-molecule GLP-1 program faces...